
Overview
Dr. Arpita Desai is a medical oncologist who specializes in caring for patients with genitourinary cancers (cancers of the genital or urinary organs). She particularly focuses on kidney and prostate cancers. She serves as medical director of the genitourinary medical oncology program at UCSF, where she leads efforts to deliver multidisciplinary, patient-centered care and advance innovative treatments. She also leads the UCSF kidney cancer program, which brings together clinical care, translational research and innovation to improve outcomes for patients with renal cell carcinoma. She also serves as medical director of the UCSF Von Hippel–Lindau multidisciplinary clinic, which integrates oncology, genetics, nephrology, ophthalmology, neurosurgery, endocrinology and other specialties to provide comprehensive, coordinated care for patients with Von-Hippel Lindau disease (a rare genetic disorder that increases a patient's risk of tumors). Through her leadership, research and national collaborations, Desai is committed to advancing precision medicine in kidney cancer and improving the lives of patients through both cutting-edge clinical care and translational research (lab findings that can lead to improvements in real-world patient care). In research, Desai is interested in developing novel imaging and treatment strategies for renal cell carcinoma, the most common type of kidney cancer. She is particularly interested in integrating functional and molecular imaging to personalize treatment and improve patient outcomes. Her research program examines theranostics, hyperpolarized MRI and biomarker-driven approaches to optimize treatments for genitourinary cancers. Desai earned her medical degree at Rajiv Gandhi University of Health Sciences in India. She completed a residency in internal medicine at the State University of New York at Buffalo, where she served as chief resident. She completed a fellowship in medical oncology at the University of Chicago. Desai is an active member of the American Society of Clinical Oncology (ASCO) and American Association for Cancer Research and the National Comprehensive Cancer Network (NCCN) Kidney Cancer Guidelines Panel. She has received a Cancer Research Institute Investigator’s Technology Impact Award, Conquer Cancer Foundation of ASCO Merit Award and Dexter S. Levy, MD, Memorial Award for her commitment to teaching and excellence in patient care and has also been recognized with several awards for her mentorship and research.
Dr. Desai is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes.
Dr. Desai is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology and American Board Of Internal Medicine, Internal Medicine. She is actively involved in clinical research, co-authoring 32 peer reviewed articles and participating in 2 clinical trials. Dr. Desai is currently accepting new patients.
Specialties
Licenses
Board Certifications
Fellowships
Hospital Affiliations
Languages Spoken
Gender
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE MAPD
- MEDICARE SNP
- OTHER MEDICARE
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE-MEDICAID PLAN
- OTHER COMMERCIAL
- OTHER MEDICARE
- OTHER MEDICARE PART D
- PPO
- HMO
- MEDICARE SNP
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- OTHER MEDICAID
- STATE MEDICAID
- HMO
- OTHER COMMERCIAL
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
1825 Fourth St., Sixth Floor, San Francisco, CA 94158
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
2 Clinical Trials
Prostate Cancer Center
Dr. Maxwell Meng is a surgeon specializing in urologic cancers and laparoscopy. His interests in patient care include diagnosing and managing cancers of the genital and urinary organs, as well as minimally invasive treatments of both benign and malignant diseases. He is experienced in robotic surgery. Meng is active in research to develop new treatment technologies. Meng earned his medical degree at Johns Hopkins School of Medicine. He completed general surgery and urology training at UCSF, where he also completed fellowships in urologic oncology and minimally invasive surgery. Dr. Meng is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Meng is board certified in American Board Of Urology, Urology. Dr. Meng is currently accepting new patients.
Prostate Cancer Center
Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer. Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer. Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology. Dr. Porten is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Porten is board certified in American Board Of Urology, Urology. Dr. Porten is currently accepting new patients.
Genitourinary Medical Oncology Clinic
Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer. As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment. Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology. Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award. Dr. Aggarwal is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Orchiectomy, and Prostatectomy. Dr. Aggarwal is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Aggarwal is currently accepting new patients.
Prostate Cancer Center
Dr. Vadim S. Koshkin is a genitourinary oncologist who specializes in caring for adults with bladder, prostate, kidney and testicular cancers. His personal enthusiasm for travel informs his approach to care, as he likes to hear about where his patients come from in order to better understand who they are. In his research, Koshkin designs and carries out clinical trials of treatments for bladder and prostate cancers. He has a particular focus on the role of immunotherapy, or treatments that stimulate a patient's own immune system to help fight cancer. He also studies targeted treatments that are aimed against specific mutations in the DNA of tumor cells, which make these tumors more vulnerable to particular drugs. This allows for the delivery of personalized treatment based on individual characteristics of patients and their tumors. After earning his medical degree at the University of Chicago Pritzker School of Medicine, Koshkin completed a residency in internal medicine at the University of Michigan. He then completed a fellowship in hematology and oncology at the Cleveland Clinic. He belongs to the American Society of Clinical Oncology, American Association for Cancer Research and Bladder Cancer Advocacy Network. A history and trivia buff, Koshkin loves to read. He also follows soccer and Chicago sports teams in his free time. Dr. Koshkin is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Non-Muscle Invasive Bladder Cancer, and Lymphadenectomy. Dr. Koshkin is board certified in American Board Of Internal Medicine, Medical Oncology and American Board Of Internal Medicine, Internal Medicine. Dr. Koshkin is currently accepting new patients.
Endocrine Surgery And Oncology Clinic
Dr. Julie Ann Sosa is an endocrine surgeon who specializes in thyroid cancer. She also has expertise in treating adults and children for a variety of benign and malignant endocrine conditions of the thyroid, parathyroid and adrenal glands. She chairs the UCSF Department of Surgery. Sosa's research focuses on developing treatments for advanced thyroid cancer and understanding environmental factors that can raise a person's risk for the disease. She also has published extensively on predictors of optimal patient outcomes following a variety of cancer-based procedures. Sosa earned her medical degree at Johns Hopkins University School of Medicine, where she also completed the Halsted residency in general surgery and served as chief resident. She completed a fellowship in clinical research with the Robert Wood Johnson Foundation at Johns Hopkins, where she was also assistant chief of service and an instructor. She has a master's degree in human sciences from the University of Oxford. Prior to joining UCSF, she was chief of endocrine surgery at Duke University, and held leadership positions at the Duke Cancer Institute and Duke Clinical Research Institute. Sosa is a fellow of the American College of Surgeons. She is the elected editor-in-chief of the World Journal of Surgery, and had previous positions as deputy editor of JAMA Surgery and associate editor of the Journal of Surgical Research. She serves on the editorial boards of seven medical journals, including the Annals of Surgery, Surgery, Annals of Surgical Oncology, Endocrine and International Journal of Endocrine Oncology. She serves on the boards of the Society of Surgical Oncology, International Thyroid Oncology Group, Association for Academic Surgery Foundation and American Thyroid Association, where she is also treasurer. She is the Leon Goldman, MD Distinguished Professor of Surgery at UCSF. Sosa was born in Montréal and raised in upstate New York. Dr. Sosa is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Thyroid Cancer, Papillary Thyroid Cancer, Parathyroid Cancer, Thyroidectomy, and Parathyroidectomy. Dr. Sosa is board certified in American Board Of Surgery, General Surgery. Dr. Sosa is currently accepting new patients.
Gastrointestinal Medical Oncology Clinic
Dr. Andrew H. Ko is a specialist in digestive system cancers. He provides compassionate and individualized care for patients with cancers of the pancreas, stomach and esophagus. In research, Ko has long been active in developing and evaluating new treatments for gastrointestinal cancers, including molecularly targeted agents and immune-based therapies. Ko earned an undergraduate degree in applied mathematics and biology at Brown University. He earned his medical degree at the Johns Hopkins University School of Medicine. He completed a residency in internal medicine at Beth Israel Deaconess Medical Center, an affiliate of Harvard Medical School, and completed a fellowship in medical oncology at Stanford University. He joined UCSF in 2001. Dr. Ko is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Stomach Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Ko is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Ko is currently accepting new patients.
Frequently Asked Questions about Dr. Arpita K. Desai
How do I make an appointment with Dr. Arpita K. Desai?
You can book an appointment with Dr. Arpita K. Desai by calling their office at 415-476-4616. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.
Is Dr. Arpita K. Desai a top-rated expert for Renal Cell Carcinoma (RCC)?
MediFind is an objective health platform that identifies experts based on real-world data. Dr. Arpita K. Desai is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
What conditions does Dr. Arpita K. Desai specialize in?
While Dr. Arpita K. Desai is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, and Chromophobe Renal Cell Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.
Does Dr. Arpita K. Desai participate in research or clinical trials?
Yes. Dr. Arpita K. Desai has published 32 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Arpita K. Desai's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Does Dr. Arpita K. Desai accept my insurance?
Dr. Arpita K. Desai accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 415-476-4616 to verify that your specific plan is currently accepted before your visit.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Chromophobe Renal Cell CarcinomaDr. Desai isDistinguished. Learn about Chromophobe Renal Cell Carcinoma.
- Clear Cell SarcomaDr. Desai isDistinguished. Learn about Clear Cell Sarcoma.
- Familial Prostate CancerDr. Desai isDistinguished. Learn about Familial Prostate Cancer.
- Familial Wilms Tumor 2Dr. Desai isDistinguished. Learn about Familial Wilms Tumor 2.
- Renal Cell Carcinoma (RCC)Dr. Desai isDistinguished. Learn about Renal Cell Carcinoma (RCC).
- Wilms TumorDr. Desai isDistinguished. Learn about Wilms Tumor.
- WT1-Related Wilms Tumor SyndromesDr. Desai isDistinguished. Learn about WT1-Related Wilms Tumor Syndromes.
- Advanced
- Adult Soft Tissue SarcomaDr. Desai isAdvanced. Learn about Adult Soft Tissue Sarcoma.
- Prostate CancerDr. Desai isAdvanced. Learn about Prostate Cancer.
- Experienced
- Bladder CancerDr. Desai isExperienced. Learn about Bladder Cancer.
- Hypothalamic HamartomasDr. Desai isExperienced. Learn about Hypothalamic Hamartomas.
- Lung AdenocarcinomaDr. Desai isExperienced. Learn about Lung Adenocarcinoma.
- Lung CancerDr. Desai isExperienced. Learn about Lung Cancer.
- MesotheliomaDr. Desai isExperienced. Learn about Mesothelioma.
- Metastatic Pleural TumorDr. Desai isExperienced. Learn about Metastatic Pleural Tumor.
- Muscle Invasive Bladder CancerDr. Desai isExperienced. Learn about Muscle Invasive Bladder Cancer.
- Non-Muscle Invasive Bladder CancerDr. Desai isExperienced. Learn about Non-Muscle Invasive Bladder Cancer.
- Urothelial CancerDr. Desai isExperienced. Learn about Urothelial Cancer.





